DOI 10.1080/13651501.2025.2576205
A systematic review and meta-analysis of the efficacy of ketamine compared to electroconvulsive therapy for treatment-resistant depression.
Аннотация
BACKGROUND
Electroconvulsive therapy (ECT) has long been considered the main method of treatment for patients with resistant major depressive disorder (MDD). Recent studies have shown that ketamine infusion can also effectively improve treatment-resistant MDD. Thus, we conducted this meta-analysis to compare the efficacy of ketamine with ECT for treating treatment-resistant depression.
METHODS
We systematically searched PubMed, the Cochrane Library, Scopus and Web of Science from the inception to 2 October 2024, to identify clinical trials and randomised controlled trials comparing the effect of ketamine with ECT on treatment-resistant major depression.
RESULTS
Six studies with 353 individuals in the ketamine group and 323 individuals in the ECT group were included. No significant differences were observed between ECT and ketamine in terms of response to treatment (RR 1.03, 95% CI (0.78, 1.37), I2 = 77.14%, T2 = 0.08), MADRS score (weighted mean difference (WMD) 0.98, 95% CI (-5.04, 7.00), I2 = 94.74%, T2 = 26.52), remission (RR 0.65, 95% CI (0.16, 2.64), I2 = 89.77%, T2 = 1.19), relapse (RR 0.93, 95% CI (0.50, 1.72), I2 = 20.13%, T2 = 0.04) and the number of those experiencing adverse events (RR 0.72, 95% CI (0.47, 1.10), I2 = 0.00%, T2 = 0.00).
CONCLUSION
These findings suggest that ketamine is not inferior to ECT for treating MDD; however, future studies are needed for validation.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.